NCT00439413

Selegiline for Smoking Cessation - 1

Phase 2, Double-Blind, Placebo-Controlled Trial of Selegiline Transdermal System (STS) as an Aid for Smoking Cessation.

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 246 (actual)
• Sponsor: National Institute on Drug Abuse (NIDA) · NIH
• Sex: All
• Age: 18 Years – 99 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is designed to examine the effects of Selegiline Transdermal System and behavioral intervention in smoking cessation as compared to behavioral intervention alone.

Conditions

• Nicotine Dependence

Interventions

Type	Name	Description
DRUG	Selegiline Transdermal Patch	Selegiline cm(2) via transdermal system
DRUG	Placebo	Matching placebo via transdermal system
BEHAVIORAL	Smoking Cessation Counseling	Subjects were provided with on-site, individual smoking cessation counseling sessions 1x per week for 9 weeks

Timeline

• Start date: 2007-06-01
• Primary completion: 2008-08-01
• Completion: 2009-01-01
• First posted: 2007-02-23
• Last updated: 2017-02-02
• Results posted: 2016-10-13

Locations

4 sites across 1 country: United States